Compare SOAR & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOAR | PHIO |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 11.2M |
| IPO Year | N/A | 2011 |
| Metric | SOAR | PHIO |
|---|---|---|
| Price | $0.17 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 25.7M | 124.2K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.28 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $0.81 |
| 52 Week High | $4.36 | $4.19 |
| Indicator | SOAR | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 37.44 |
| Support Level | $0.12 | $0.81 |
| Resistance Level | $0.27 | $1.15 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 22.42 | 17.74 |
Volato Group Inc is an aviation technology company that connects travelers to private, on-demand flight access and develops proprietary software platforms for enterprise and operational applications. The company operates in a single operating and reportable segment, private aviation services. It operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.